-
1Academic Journal
المؤلفون: Jason van Leuven, Simon Evans, Ganessan Kichenadasse, Neeltje Steeghs, Billie Bonevski, Gerd Mikus, Madelé van Dyk
المصدر: Cancers; Volume 15; Issue 13; Pages: 3293
مصطلحات موضوعية: implementation science, individualised dosing, personalised medicine, therapeutic drug monitoring, oral anti-cancer drugs
وصف الملف: application/pdf
-
2Academic Journal
المؤلفون: E. Sánchez Gómez, Y. Arco Prados
المصدر: Farmacia Hospitalaria, Vol 38, Iss 4, Pp 338-363 (2014)
مصطلحات موضوعية: Abstract: Objective: To identify the pharmacologic interactions of oral anti-cancer drugs provided at an outpatient clinic. Material and methods: Anti-cancer drugs included in the Phamacotherapeutic Guideline of the Hospital were identified. A literature search was carried out on the pharmacologic interactions in MEDLINE® and EMBASE® (with the filer language English or Spanish, and the descriptors: “name of the anti-cancer drug” AND (“drug interactions” OR “pharmacokinetic”)), Up-to-date®, MICROMEDEX® and the drug information sheet for the EMA and the FDA. Information was also gathered from the abstract presented to European and Spanish scientific meetings for the last 4 years. When an interaction was analyzed and had clinical relevance, the best pharmacotherapeutic interaction-free alternative was sought. Results: Twenty-three drugs were identified, of which Chlorambucil, Fludarabine, Lenalidomide, Melphalan, and Thalidomide were the active compounds with the lowest likelihood of producing a pharmacologic interaction. Tyrosine kinase inhibitors (particularly Erlotinib, Imatinib, Lapatinib, and Pazopanib) are the drugs with highest number of pharmacologic interactions described, many of them with severe clinical consequences, with increases and decreases of the plasma levels of anti-cancer drugs. The active compounds identified that may have pharmacologic interactions with anticancer drugs were mainly: Allopurinol, Amiodarone, Carbamazepine, Dabigatran, Digoxin, Spironolactone, Phenytoin, Itraconazol, Repaglinide, Silodosin, Tamoxifen, Verapamil, and Warfarin. Pharmacologic interactions through the cytochrome P450 1A2, 2D6, 2C8, 2C9, 3A4 were the most important for tyrosine kinase inhibitors. Other non-pharmacologic compounds, with an important potential of producing relevant pharmacologic interaction were immunomodulators (Echinacea extracts) and Hypericum perforatum. Conclusions: Oral anticancer drugs have numerous pharmacologic interactions that should be monitored during pharmacotherapy. Given its position, Pharmacokinetics, Pharmacologic interaction, Out-patients, Oral chemotherapy, Pharmacy Department, Pharmacy and materia medica, RS1-441, Therapeutics. Pharmacology, RM1-950
وصف الملف: electronic resource
-
3Academic Journal
المؤلفون: Fumiyuki Watanabe, Haruka Hori, Toshiichi Seki, Toshiyuki Hirai, Yuji Akiyama, Yusuke Terakado, 堀 晴香, 寺門 祐介, 平井 利幸, 渡邉 文之, 秋山 裕史, 関 利一
المصدر: 薬局薬学 / The Journal of Community Pharmacy and Pharmaceutical Sciences. 2019, 11(1):53
-
4
المؤلفون: Maureen E. Trudeau, Matthew C. Cheung, Judy Truong, Helen Mai, Kelvin K. W. Chan, Alexandra Chambers, Mona Sabharwal
المصدر: Cancer Medicine, Vol 8, Iss 8, Pp 3770-3781 (2019)
Cancer Medicineمصطلحات موضوعية: 0301 basic medicine, Cancer Research, Canada, Cost-Benefit Analysis, Antineoplastic Agents, Dose level, lcsh:RC254-282, Oral Anti-Cancer Drugs, Drug Costs, Toxicology, 03 medical and health sciences, 0302 clinical medicine, cost analysis, Neoplasms, Medicine, Humans, health economics, Radiology, Nuclear Medicine and imaging, Public Health Surveillance, pricing strategy, health care economics and organizations, Original Research, cancer drug price(s), anti‐cancer (anticancer) drugs, business.industry, Clinical Cancer Research, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cost analysis, Oncology drug, Dose reduction, business, anti‐cancer (anticancer) medications
-
5
المؤلفون: Kathryn Djordjevic, Venetia Bourrier, Mova Leung, Mark Pasetka, Kathy Vu, Philip Emberley, Justin J Bates, Heather Logan, Rick Abbott, Julie Greenall, Erika N Brown, Louise Paquet
المصدر: Journal of Oncology Pharmacy Practice. 25:674-688
مصطلحات موضوعية: Pharmacies, Canada, Community pharmacies, medicine.medical_specialty, Consensus, business.industry, Antineoplastic Agents, Pharmacy, Community Pharmacy Services, Safe handling, Oral Anti-Cancer Drugs, 03 medical and health sciences, 0302 clinical medicine, Oncology, Community pharmacy, 030220 oncology & carcinogenesis, Family medicine, Humans, Medicine, Pharmacology (medical), Pharmacy practice, business, 030215 immunology
-
6
المؤلفون: Frank Dörje, Katja Schlichtig, Martin F. Fromm, Pauline Dürr
مصطلحات موضوعية: medicine.medical_specialty, food.ingredient, business.industry, Treatment outcome, MEDLINE, General Medicine, Review Article, Oral Anti-Cancer Drugs, Grapefruit juice, Gastric ph, Bioavailability, Poor adherence, 03 medical and health sciences, 0302 clinical medicine, food, Pharmacokinetics, 030220 oncology & carcinogenesis, medicine, 030212 general & internal medicine, Intensive care medicine, business
-
7
المؤلفون: G Larhantec, N Mugnier, B Rey-Rubio, C Renard, G Dozias, M Perennes
المصدر: Section 4: Clinical Pharmacy Services.
مصطلحات موضوعية: Clinical pharmacy, medicine.medical_specialty, Quality of life, business.industry, Family medicine, Pharmacist, Conflict of interest, Short answer, medicine, In patient, Survey research, business, Oral Anti-Cancer Drugs
-
8Academic Journal
المؤلفون: Chimi An, Fusao Komada, Hiroyuki Hichiya, Kazuho Tanaka, Mamoru Seto, Manabu Amano, Naomi Kurata, Tetsuo Inoue, Yoshifumi Kiyohara, Yoshito Zamami, 井上 徹雄, 倉田 なおみ, 天野 学, 安 智美, 座間味 義人, 比知屋 寛之, 清原 義史, 瀬戸 衛, 田中 一穂, 駒田 富佐夫
المصدر: 社会薬学 / Japanese Journal of Social Pharmacy. 2013, 32(2):43
-
9Academic Journal
المؤلفون: Chimi AN, Erika BAN, Fusao KOMADA, Hiroyuki HICHIYA, Kaoru AZUMA, Kazuho TANAKA, Manabu AMANO, Naomi KURATA, Rumi NAKAHARA, Sachiko KAKEI, Tetsuo INOUE, Tomohide NISHIRAKU, Yoshifumi KIYOHARA, Yoshito ZAMAMI, Yukiko OHTAKE, 中原 瑠美, 井上 徹雄, 伴 英里香, 倉田 なおみ, 大竹 祐貴子, 天野 学, 安 智美, 座間味 義人, 東 薫, 比知屋 寛之, 清原 義史, 田中 一穂, 筧 幸子, 西楽 丈嗣, 駒田 富佐夫
المصدر: Annual Meeting of the Japanese Society of Toxicology. 2013, :1001011
-
10
المؤلفون: Satoko Hori, Yasufumi Sawada, Hiroki Satoh, Akiko Miki, Yumiko Fujita
المصدر: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 39:741-749
مصطلحات موضوعية: medicine.medical_specialty, business.industry, Condition survey, Internal medicine, medicine, business, Oral Anti-Cancer Drugs
-
11Conference
المؤلفون: Ely, Tracy
المصدر: Master of Science in Health Policy Capstone Presentations
مصطلحات موضوعية: Medication Adherence in Oncology: The Role of Oral Anti-Cancer Drugs and Copayments, capstone, Jefferson School of Population Health, Thomas Jefferson University, Public Health
وصف الملف: video/mp4
Relation: https://jdc.jefferson.edu/mshp/9; https://jdc.jefferson.edu/context/mshp/article/1008/type/native/viewcontent
-
12
المؤلفون: A. Gohari, P. Paubel, O. Marquestaut, B. Mittaine-Marzac, R. Farinotti
المصدر: Value in Health. 19:A459-A460
مصطلحات موضوعية: business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine, Medical emergency, medicine.disease, business, Oral Anti-Cancer Drugs
-
13
المؤلفون: Mona Sabharwal, Maureen E. Trudeau, Judy Truong, Matthew C. Cheung, Helen Mai, Alexandra Chambers, Kelvin K. W. Chan
المصدر: Journal of Clinical Oncology. 35:e18312-e18312
مصطلحات موضوعية: Drug, Cancer Research, medicine.medical_specialty, business.industry, media_common.quotation_subject, Affect (psychology), Oral Anti-Cancer Drugs, Oncology, medicine, Intensive care medicine, business, health care economics and organizations, media_common, Event (probability theory)
-
14
المؤلفون: E. Sánchez Gómez, Y. Arco Prados
المصدر: Farmacia Hospitalaria, Volume: 38, Issue: 4, Pages: 338-363, Published: AUG 2014
Farmacia Hospitalaria, Vol 38, Iss 4, Pp 338-363 (2014)مصطلحات موضوعية: Digoxin, many of them with severe clinical consequences, Quimioterapia oral, of which Chlorambucil, Amiodarone, lcsh:Medicine, lcsh:RS1-441, Pacientes externos, Spironolactone, Oral chemotherapy, Servicio de farmacia, 3A4 were the most important for tyrosine kinase inhibitors. Other non-pharmacologic compounds, the best pharmacotherapeutic interaction-free alternative was sought. Results: Twenty-three drugs were identified, Pharmacologic interaction, lcsh:Pharmacy and materia medica, Fludarabine, and the descriptors: “name of the anti-cancer drug” AND (“drug interactions” OR “pharmacokinetic”)), Silodosin, MICROMEDEX® and the drug information sheet for the EMA and the FDA. Information was also gathered from the abstract presented to European and Spanish scientific meetings for the last 4 years. When an interaction was analyzed and had clinical relevance, Interacción farmacológica, Abstract: Objective: To identify the pharmacologic interactions of oral anti-cancer drugs provided at an outpatient clinic. Material and methods: Anti-cancer drugs included in the Phamacotherapeutic Guideline of the Hospital were identified. A literature search was carried out on the pharmacologic interactions in MEDLINE® and EMBASE® (with the filer language English or Spanish, Pharmacokinetics, Itraconazol, with an important potential of producing relevant pharmacologic interaction were immunomodulators (Echinacea extracts) and Hypericum perforatum. Conclusions: Oral anticancer drugs have numerous pharmacologic interactions that should be monitored during pharmacotherapy. Given its position, Lenalidomide, Melphalan, 2D6, and Thalidomide were the active compounds with the lowest likelihood of producing a pharmacologic interaction. Tyrosine kinase inhibitors (particularly Erlotinib, and Pazopanib) are the drugs with highest number of pharmacologic interactions described, lcsh:R, Lapatinib, Dabigatran, Repaglinide, with increases and decreases of the plasma levels of anti-cancer drugs. The active compounds identified that may have pharmacologic interactions with anticancer drugs were mainly: Allopurinol, Tamoxifen, Carbamazepine, Verapamil, and Warfarin. Pharmacologic interactions through the cytochrome P450 1A2, Farmacocinética, Up-to-date®, Out-patients, Pharmacy Department, Phenytoin, Imatinib, 2C8, 2C9
وصف الملف: text/html
-
15
المؤلفون: R. van Leeuwen, Ron H.J. Mathijssen, Cees Neef, David M. Burger, Daniel H.S. Brundel, T. van Gelder, Frank G A Jansman
المصدر: Annals of Oncology, 23(Suppl. 9):1402P, 456-456. Oxford University Press
مصطلحات موضوعية: Drug, Oncology, medicine.medical_specialty, business.industry, media_common.quotation_subject, Cancer, Hematology, medicine.disease, Oral Anti-Cancer Drugs, Internal medicine, medicine, business, media_common
-
16
المصدر: Journal de gestion et d'économie médicales | 36 | 1 | 2018-05-23 | p. 3-16 | 2262-5305
-
17
المؤلفون: Peggy Eastman
المصدر: Oncology Times. 23:4
مصطلحات موضوعية: medicine.medical_specialty, business.industry, medicine, Intensive care medicine, business, Reimbursement, Oral Anti-Cancer Drugs
Full Text Finder